Midbrain Dopaminergic Progenitor Cell Purification

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for purifying midbrain dopaminergic neural progenitor cells (mDA NPs) are inefficient due to the lack of reliable single markers, leading to heterogeneous cell populations and complications in transplantation therapies for neurodegenerative diseases like Parkinson's disease, with fetal cell transplantation being limited by ethical concerns and ESC-derived cells posing risks of tumor formation and graft-induced dyskinesia.

Innovation Solution

The discovery and characterization of midbrain dopaminergic neural progenitor cells expressing Corin and Frizzled-5 (Fzd5) markers, along with additional markers like Otx2, FoxA2, and Lmx1a, enable specific purification and expansion of homogeneous mDA NP populations using flow cytometry and controlled differentiation protocols.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If fetal DA cell transplantation is used, then proof-of-principle of cell-based therapy is achieved, but ethical controversies and lack of standardized cells limit its use

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidstandardization and ethical acceptability

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent uses embryonic stem cells as a renewable copy-source to generate midbrain dopaminergic neurons, replacing the need for fetal cells. This copying approach maintains therapeutic effectiveness while avoiding ethical controversies and enabling standardization through immortalized stem cell lines that can be expanded indefinitely

Inventive Principle:

Principle #26Copying

2Quantity of substance

If ESC-derived cells are used for transplantation, then unlimited cell source is provided, but heterogeneous population causes difficult control of function and tumor formation risks

Engineering Contradiction:

Improvecell availabilityVSAvoidfunctional control and safety

Core Design Contradiction:

Quantity of substanceVSReliability

Solution Approach 1:

The patent extracts and isolates specific midbrain dopaminergic neural progenitor cells from heterogeneous embryonic stem cell populations using flow cytometry with specific surface markers (TH, DAT, VMAT2). This extraction process separates the desired functional cell type from other cell types, enabling controlled transplantation with reduced tumor risk while maintaining unlimited cell availability

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent replaces traditional mechanical/manual cell sorting methods with flow cytometry-based automated sorting using fluorescently labeled antibodies against specific markers. This substitution enables precise, rapid, and reproducible separation of midbrain dopaminergic progenitors from heterogeneous populations, improving both purity and functional control

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Quantity of substance

If ESC-derived progenies are transplanted, then unlimited cell source is available, but immature cells and residual pluripotent cells form tumors

Engineering Contradiction:

Improvecell source availabilityVSAvoidtumor formation risk

Core Design Contradiction:

Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The patent performs preliminary differentiation of embryonic stem cells into midbrain dopaminergic neural progenitor cells before transplantation, and further matures them in vitro for extended periods. This preliminary maturation process ensures that transplanted cells are fully differentiated and have lost pluripotency, eliminating tumor formation risk while maintaining unlimited cell source availability through continued in vitro expansion of mature cells

Inventive Principle:

Principle #10Preliminary action

4Reliability

If fetal cell transplantation is used, then cell-based therapy proof-of-principle is demonstrated, but graft-induced dyskinesia complications occur

Engineering Contradiction:

Improvetherapeutic proofVSAvoidgraft-induced dyskinesia

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent ensures that transplanted cells are highly purified midbrain dopaminergic neural progenitor cells with specific marker expression profiles (TH+, DAT+, VMAT2+). This local quality control through precise phenotypic specification ensures that only the desired dopaminergic cell type is transplanted, preventing graft-induced dyskinesia caused by misplaced or wrong cell types while maintaining therapeutic effectiveness

Inventive Principle:

Principle #3Local quality

Data Source

PatentEP2980209B1Neuronal progenitor cells and uses

Publication Date: 2018.01.10 THE MCLEAN HOSPITAL CORP

Figure 1A~1B
Figure 2
Figure 3A~3C

AI summary

Provided are methods of isolating a novel cell population of midbrain dopaminergic neuronal progenitor cells derived from stem cells using a novel combination markers. The cell population may be used for cell therapies for the treatment of Parkinson's disease and as substrates in pharmacological assays.